Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-039775
Filing Date
2023-11-07
Accepted
2023-11-07 17:02:23
Documents
49
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 829856
2 ex31-1.htm EX-31.1 11140
3 ex31-2.htm EX-31.2 11353
4 ex32-1.htm EX-32.1 4428
5 ex32-2.htm EX-32.2 4312
  Complete submission text file 0001493152-23-039775.txt   4222092

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE thar-20230930.xsd EX-101.SCH 28792
7 XBRL CALCULATION FILE thar-20230930_cal.xml EX-101.CAL 34105
8 XBRL DEFINITION FILE thar-20230930_def.xml EX-101.DEF 144402
9 XBRL LABEL FILE thar-20230930_lab.xml EX-101.LAB 272149
10 XBRL PRESENTATION FILE thar-20230930_pre.xml EX-101.PRE 226709
43 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 544624
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41210 | Film No.: 231384944
SIC: 2834 Pharmaceutical Preparations